Intersect ENT Stock Forecast, Price & News

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

Is Intersect ENT a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT or view top-rated stocks.

How has Intersect ENT's stock price been impacted by Coronavirus?

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XENT stock has increased by 26.0% and is now trading at $27.09.
View which stocks have been most impacted by COVID-19.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Intersect ENT.

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The medical equipment provider earned $24.40 million during the quarter, compared to analyst estimates of $29.63 million. Intersect ENT had a negative net margin of 85.02% and a negative trailing twelve-month return on equity of 151.36%.
View Intersect ENT's earnings history.

What price target have analysts set for XENT?

5 equities research analysts have issued 12-month price objectives for Intersect ENT's stock. Their forecasts range from $23.00 to $28.30. On average, they expect Intersect ENT's stock price to reach $26.95 in the next year. This suggests that the stock has a possible downside of 0.5%.
View analysts' price targets for Intersect ENT or view top-rated stocks among Wall Street analysts.

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the following people:

• Thomas A. West, President, Chief Executive Officer & Director
• Randy Meier, Chief Financial Officer & Executive Vice President
• Patrick A. Broderick, Secretary, Executive VP & General Counsel
• Mark L. Alley, Vice President-Sales
• Reyna M. Fernandez, Chief Human Resource Officer

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT CEO Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Intersect ENT's key competitors?

Some companies that are related to Intersect ENT include Beauty Health (SKIN), Nevro (NVRO), AtriCure (ATRC), iRhythm Technologies (IRTC), Haemonetics (HAE), NuVasive (NUVA), Axonics (AXNX), Glaukos (GKOS), Paragon 28 (FNA), Silk Road Medical (SILK), Procept BioRobotics (PRCT), Atrion (ATRI), Inovio Pharmaceuticals (INO), OrthoPediatrics (KIDS) and Pulmonx (LUNG).
View all of XENT's competitors.

What other stocks do shareholders of Intersect ENT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG), Air Transport Services Group (ATSG), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and AbbVie (ABBV).

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.75%), Magnetar Financial LLC (7.64%), Versor Investments LP (6.76%), Millennium Management LLC (4.71%), Artisan Partners Limited Partnership (4.35%) and Alpine Associates Management Inc. (4.16%). Company insiders that own Intersect ENT stock include Richard A Meier and Thomas A West.
View institutional ownership trends for Intersect ENT.

Which institutional investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Polar Asset Management Partners Inc., BlackRock Inc., Neuberger Berman Group LLC, UBS Group AG, Dimensional Fund Advisors LP, Citadel Advisors LLC, and New York State Common Retirement Fund.
View insider buying and selling activity for Intersect ENT or view top insider-selling stocks.

Which institutional investors are buying Intersect ENT stock?

XENT stock was purchased by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Versor Investments LP, Millennium Management LLC, Alpine Associates Management Inc., Morgan Stanley, Alliancebernstein L.P., Omni Partners US LLC, and CNH Partners LLC. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT or or view top insider-buying stocks.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $27.09.

How much money does Intersect ENT make?

Intersect ENT has a market capitalization of $906.43 million and generates $80.55 million in revenue each year. The medical equipment provider earns $-72.32 million in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does Intersect ENT have?

Intersect ENT employs 406 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is www.intersectent.com.

Where are Intersect ENT's headquarters?

Intersect ENT is headquartered at 1555 ADAMS DRIVE, MENLO PARK CA, 94025.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at (650) 641-2100, via email at [email protected], or via fax at 866-736-1251.